4 recruiting, 3 not yet recruiting. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 4, Not yet recruiting 3 |
| Phase 2 | 3 | Not yet recruiting 3 |
Follow HIV -1 Infection: new trials by email Literature Review of HIV -1 Infection trials Research Report on HIV -1 Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life Broadly neutralizing antibody (bNAb) ePGT121v1-LS, Saline (0.9% NaCl) - HIV -1 Infection | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario 12 de Octubre | 87 | 2027-01-01 | 2026-08-20 |
| Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life (2) Broadly neutralizing antibody (bNAb) ePGT121v1-LS, Saline (0.9% NaCl), Broadly neutralizing antibody (bNAb) VRC07-523-LS - HIV -1 Infection | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario 12 de Octubre | 73 | 2027-01-01 | 2026-08-20 |
| A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV BNT168, Placebo - HIV -1 Infection | Phase 1 | Recruiting | BioNTech SE | 126 | 2026-08-04 | 2026-10-14 |
| Study of GS-0415 and How It Works in People With HIV GS-0415, GS-0415 Placebo - HIV -1 Infection | Phase 1 | Recruiting | Gilead Sciences | 112 | 2026-07-22 | 2026-09-23 |
| Combining Latency Reversing Agents to Address the HIV Reservoir Pyrimethamine (PYR), Lenalidomide, Topiramate (drug) - HIV (Human Immunodeficiency Virus), HIV -1 Infection | Phase 1 / Phase 2 | Not yet recruiting | Erasmus Medical Center | 30 | 2026-04-01 | 2026-02-03 |
| A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV BNT351, Placebo - HIV -1 Infection | Phase 1 | Recruiting | BioNTech SE | 67 | 2026-02-09 | 2026-09-01 |
| Safety Study of MucoCept-CVN Live Biotherapeutic Product L. jensenii 1153-1666, Placebo - HIV -1 Infection | Phase 1 | Recruiting | Craig Cohen, MD, MPH | 12 | 2025-10-06 | 2026-10-16 |
Acquired Immunodeficiency Syndrome (2)
Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2) · HIV Infections (2) · Immune System Diseases (2) · Immunologic Deficiency Syndromes (2) · Infections (2) · Lentivirus Infections (2) · RNA Virus Infections (2) · Retroviridae Infections (2) · Sexually Transmitted Diseases (2) · Sexually Transmitted Diseases, Viral (2) · Slow Virus Diseases (2) · Urogenital Diseases (2) · Virus Diseases (2)
Broadly Neutralizing Antibodies (2) · Sodium Chloride (2) · Lenalidomide (1) · Pharmaceutical Preparations (1) · Pyrimethamine (1) · Topiramate (1)
BioNTech SE (2) · Hospital Universitario 12 de Octubre (2) · Craig Cohen, MD, MPH (1) · Erasmus Medical Center (1) · Gilead Sciences (1)
United States (4) · Germany (1) · Netherlands (1) · South Africa (1)
Casper Rokx, MD PhD (1) · Craig Cohen, MD, MPH (1)
2025 (1), U01AI186333 (1)